Compare Annaly Capital Management, Inc. (NLY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Pfizer Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.87 (market cap $16.63B), while Pfizer Inc trades at $24.94 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 8.5× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.22%). Which is the better fit depends on your goals.
| NLY | PFE | |
|---|---|---|
Market Cap | $16.63B | $141.06B |
Sector | Financials | Health |
52-Week High | $24.40 | $28.56 |
52-Week Low | $19.96 | $23.29 |
Dividend Yield | 13.22% | 6.95% |
Volume | — | 29,869,932 |
Enterprise Value | — | $191.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $22.65, down 1.56% today, with a bullish technical signal and consistent earnings beats. The stock offers a high dividend yield of 13% and trades below the consensus price target of $24.80. Recent Q2 2026 results highlight strong net interest income growth, though mortgage market volatility remains a concern.
Outlook is positive with analyst support (57% buy ratings), but risks include interest rate sensitivity and leverage. The stock presents income opportunity with upside potential, but investors should weigh dividend sustainability against macroeconomic headwinds.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
